KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma

Decroos, Amandine; Cheminant, Morgane; Bruneau, Julie; Carras, Sylvain; Parinet, Vincent; Pelletier, Laura; Lacroix, Laetitia; Martin, Nadine; Giustiniani, Jérôme; Lhermitte, Ludovic; Asnafi, Vahid; Battistella, Maxime; Lemonnier, François; Leval, Laurence de; Sicard, Hélène; Bonnafous, Cécile; Gauthier, Laurent; Genestier, Laurent; Caruso, Stefano; Gaulard, Philippe; Hermine, Olivier; Ortonne, Nicolas

doi:10.3324/haematol.2022.282220

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 In a recent study, Decroos et al proposed KIR3DL2 as a promising candidate for enhancing the management of aggressive systemic peripheral T-cell lymphomas. 38 Additionally, KIR3DL2 binds to multiple HLA-A ligands. HLA-A has also been demonstrated to be associated with varying degrees of liver fibrosis and hepatocellular carcinoma related to HCV.…”

Section: Discussionmentioning

confidence: 99%

“…Positioned as an inhibitory receptor in the intricately functional KIR gene cluster B type, KIR3DL2 frequently exerts inhibitory effects on NK cells and T lymphocytes, contributing to the regulation of the immune system's functions 37 . In a recent study, Decroos et al proposed KIR3DL2 as a promising candidate for enhancing the management of aggressive systemic peripheral T‐cell lymphomas 38 . Additionally, KIR3DL2 binds to multiple HLA‐A ligands.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Investigating the role of killer cell immunoglobulin‐like receptors and human leukocyte antigen genetic variants in hepatitis C virus infection

Li,

Zeng,

Huang

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

The genetic diversity of killer cell immunoglobulin‐like receptors (KIRs) and human leukocyte antigen (HLA) genes influences the host's immune response to viral pathogens. This study aims to explore the impact of five single nucleotide polymorphisms (SNPs) in KIR3DL2 and HLA‐A genes on hepatitis C virus (HCV) infection. A total of 2251 individuals were included in the case‐control study. SNPs including KIR3DL2 rs11672983, rs3745902, rs1654644, and HLA‐A rs3869062, rs12202296 were genotyped. By controlling various confounding factors using a modified logistic regression model, as well as incorporating stratified analysis, joint effects analysis, and multidimensional bioinformatics analysis, we analyzed the relationship between SNPs and HCV infection. The logistic regression analysis showed a correlation between KIR3DL2 rs11672983 AA, KIR3DL2 rs3745902 TT, and increased HCV susceptibility (p < 0.01). Stratified analysis indicated that KIR3DL2 rs1654644 and HLA‐A rs3869062 also heightened HCV susceptibility in certain subgroups. A linear trend of rising HCV infection rates was observed when combining KIR3DL2 rs11672983 AA and KIR3DL2 rs3745902 TT (ptrend = 0.007). Bioinformatics analysis suggested these SNPs' regulatory potential and their role in altering messenger RNA secondary structure, implying their functional relevance in HCV susceptibility. Our findings indicate that KIR3DL2 rs11672983 AA and KIR3DL2 rs3745902 TT are significantly associated with increased susceptibility to HCV infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Investigating the role of killer cell immunoglobulin‐like receptors and human leukocyte antigen genetic variants in hepatitis C virus infection

Li,

Zeng,

Huang

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Ong,

Zain

2024

American J Hematol

View full text Add to dashboard Cite

IntroductionAggressive T‐cell lymphomas continue to have a poor prognosis. There are over 30 different subtypes of peripheral T‐cell lymphoma (PTCL), and we are now beginning to understand the differences between the various subtypes beyond histologic variations.Molecular Pathogenesis of Various Subtypes of PTCLGene expression profiling and other molecular techniques have enabled deeper understanding of differences in various subtypes as reflected in the latest 5th WHO classification of PTCL. It is becoming increasingly clear that therapeutic approaches that target specific cellular pathways are needed to improve the clinical outcomes of PTCL.Targeted TherapiesThere are many targeted agents currently in various stages of clinical trials for PTCL that take advantage of the differential expression of specific proteins or receptors in PTCL tumors. This includes the CD30 directed antibody drug conjugate brentuximab vedotin. Other notable targets are phosphatidylinositol 3‐kinase inhibitors, histone deacetylase inhibitors, CD25, and chemokine receptor 4. Anaplastic lymphoma kinase (ALK) inhibitors are promising for ALK expressing tumors.ImmunotherapiesAllogeneic stem cell transplant continues to be the curative therapy for most aggressive subtypes of PTCL. The use of checkpoint inhibitors in the treatment of PTCL is still controversial, with best results seen in cases of extranodal natural killer cell/T‐cell lymphoma. Bispecific antibody‐based treatments and chimeric antigen receptor cell‐based therapies are in clinical trials.

show abstract

Exploring the role of KIR3DL2 on NK cells in hepatocellular carcinoma and its potential prognostic implications

Zhu,

Jin,

Pan

et al. 2024

iScience

View full text Add to dashboard Cite

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma

Abstract: Not available.

Cited by 5 publications

References 15 publications

Investigating the role of killer cell immunoglobulin‐like receptors and human leukocyte antigen genetic variants in hepatitis C virus infection

Investigating the role of killer cell immunoglobulin‐like receptors and human leukocyte antigen genetic variants in hepatitis C virus infection

Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management

Exploring the role of KIR3DL2 on NK cells in hepatocellular carcinoma and its potential prognostic implications

Contact Info

Product

Resources

About